Skip to main content

Cigna Value Stock - Dividend - Research Selection

Cigna

ISIN: US1255231003 , WKN: A2PA9L

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers. This segment also provides Medicare Advantage and Medicare Part D plans to seniors, and Medicaid plans. The Global Supplemental Benefits segment offers supplemental health, life, and accident insurance products. The Group Disability and Life segment provides group long-term and short-term disability, group life, accident, and specialty insurance products and related services. The Other Operations segment offers corporate-owned life insurance products that are permanent insurance contracts sold to corporations to provide coverage; and run-off settlement annuity contracts. The company distributes its products and services through insurance brokers and insurance consultants; and directly to employers, unions and other groups, or individuals, as well as through direct response television and the Internet. Cigna Corporation was founded in 1792 and is headquartered in Bloomfield, Connecticut.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Is It Time To Reassess Cigna Group (CI) After Recent Share Price Weakness?

2026-03-28
If you have been wondering whether Cigna Group at around US$261.96 is starting to look like value, this breakdown is designed to help you weigh up the numbers with confidence. The stock has seen a 0.3% decline over the last week, a 7.9% decline over the past month, and is down 6.1% year to date and 17.7% over the last year, while the 3 year and 5 year returns are 8.4% and 18.6% respectively. Recent coverage has focused on how Cigna Group fits into broader conversations about healthcare...

1 Healthcare Stock Worth Investigating and 2 That Underwhelm

2026-03-27
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 2.4% over the past six months. Investing here would have been wise - at the same time, the S&P 500 shed 1% of its value.

Mark Cuban Calls $30,000 Corporate Healthcare Burden 'Insane,' Backs Bill To Break Up Big Medicine Giants UNH, CVS, CI

2026-03-26
Billionaire entrepreneur Mark Cuban is sounding the alarm on skyrocketing corporate healthcare costs, declaring them a primary driver of layoffs and throwing his full weight behind bipartisan legislation to dismantle healthcare conglomerates like UnitedHealth Group Inc., CVS Health Corp., and Cigna Group. The ‘Insane’ Cost Of Care In a recent social media post, the founder of Cost Plus Drugs, Cuban, argued that out-of-control medical expenses—not artificial intelligence (AI)—are forcing companie

26-year-old’s health insurance premiums spiked $700 after ACA subsidies ended: ‘Your stomach drops’

2026-03-25
With enhanced ACA subsidies expired, health insurance premiums are estimated to more than double for many marketplace enrollees.

The Cigna Group Foundation Supports More Than 8,000 Veterans Through Community-Led Housing Stability Programs

2026-03-24
The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE: CI), today released its 2025 Improving Veteran Mental Health Impact Report, highlighting the collective progress that its 22 nonprofit partners have made in supporting 8,000 veterans by expanding access to stable housing and providing integrated support services, such as transportation and legal aid.

Tracking David Einhorn's Greenlight Capital Portfolio - Q4 2025 Update

2026-03-22
Greenlight Capital’s Q4 2025 13F: portfolio up to $2.85B, top buys/sells, new stakes, and biggest holdings like GRBK & BHF.

Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?

2026-03-20
Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals.

Biotech Stock Up 372% Gets Sold as New Pick Rises 40% in 2026

2026-03-20
This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and systemic mastocytosis.

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

2026-03-20
This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance mechanisms.

HS Chief Counselor Chris Klomp, At STAT News Conference, Says They're Beginning To Read In Pharma Companies On Codifying MFN Pricing

2026-03-19
https://www.statnews.com/stat-summit-east/